[{"NetIncomeLoss_1_Q2_USD":-16110000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":25217542.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":25589947.0,"IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2_Q2_USD":-1.29,"IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1_Q2_USD":-0.63,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":5068000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-137000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q2_USD":17000000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":3760000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-51281000.0,"WeightedAverageNumberOfSharesIssuedBasic_1_Q2_shares":25589947.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":28000.0,"AssetsCurrent_0_Q2_USD":227955000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":2035091.0,"AvailableForSaleSecurities_0_Q2_USD":221477000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q2_USD":2888000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":221477000.0,"Assets_0_Q2_USD":231081000.0,"WeightedAverageNumberOfSharesIssuedBasic_2_Q2_shares":25217542.0,"GeneralAndAdministrativeExpense_2_Q2_USD":7772000.0,"DepreciationAndAmortization_1_Q2_USD":200000.0,"DepreciationAndAmortization_2_Q2_USD":536000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":13190000.0,"ProceedsFromStockPlans_2_Q2_USD":1137000.0,"IncreaseDecreaseInDeferredRevenue_2_Q2_USD":-1709000.0,"CommonStockValue_0_Q2_USD":3000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":471000.0,"AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0_Q2_USD":52255000.0,"ForeignCurrencyTransactionGainLossBeforeTax_2_Q2_USD":-108000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":140409000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":67715000.0,"DeferredRevenueNoncurrent_0_Q2_USD":967000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-32584000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-16058000.0,"OtherAssetsNoncurrent_0_Q2_USD":389000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":86220000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":465179000.0,"Liabilities_0_Q2_USD":13502000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":-68000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-18000.0,"MarketableSecuritiesCurrent_0_Q2_USD":137084000.0,"ShareBasedCompensation_2_Q2_USD":5575000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":26961000.0,"CommonStockCapitalSharesReservedForFutureIssuance_0_Q2_shares":5149674.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":2091000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":12000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-32624000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-16110000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":108000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":70000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-27826000.0,"AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0_Q2_USD":169222000.0,"WorkersCompensationLiabilityCurrent_0_Q2_USD":2272000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":7606000.0,"LiabilitiesCurrent_0_Q2_USD":10394000.0,"AccountsPayableCurrent_0_Q2_USD":2714000.0,"NonoperatingIncomeExpense_2_Q2_USD":18000.0,"NonoperatingIncomeExpense_1_Q2_USD":-29000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":4651000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":40000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":86220000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":2737000.0,"NetIncomeLoss_2_Q2_USD":-32624000.0,"DeferredRevenueCurrent_0_Q2_USD":2283000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":118705000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":61302000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-247466000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":869000.0,"OperatingIncomeLoss_2_Q2_USD":-32642000.0,"OperatingIncomeLoss_1_Q2_USD":-16081000.0,"InvestmentIncomeAmortizationOfPremium_2_Q2_USD":430000.0,"PreferredStockValue_0_Q2_USD":null,"LiabilitiesAndStockholdersEquity_0_Q2_USD":231081000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":5575000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":2888000.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":10343000.0,"OperatingExpenses_2_Q2_USD":34733000.0,"OperatingExpenses_1_Q2_USD":16950000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.29,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.63,"ProfitLoss_2_Q2_USD":-32624000.0,"OtherLiabilitiesCurrent_0_Q2_USD":329000.0,"StockholdersEquity_0_Q2_USD":217579000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":291000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":221493000.0,"DeferredRentCreditNoncurrent_0_Q2_USD":2141000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":563000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":620000.0,"Ticker":"RAPT","CIK":"1673772","name":"RAPT THERAPEUTICS, INC.","OfficialName":"RAPT Therapeutics Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"595076458.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210811"}]